Results 241 to 250 of about 139,694 (312)

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source

Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation. [PDF]

Curr Allergy Asthma Rep
Valent P, Hartmann K, Stefanzl G, Filik Y, Bauer K, Degenfeld-Schonburg L, Gleixner KV, Siebenhaar F, Niedoszytko M, Sperr WR, Aghaallaei N, Hoermann G, Sabato V, Orfao A, Arock M, Akin C.   +15 more
europepmc   +1 more source

GATA4‐Driven Transcription of HtrA1 Promotes Cellular Senescence in Ménière's Disease and Age‐Related Audio‐Vestibular Dysfunction

Advanced Science, EarlyView.
This study identifies the HDAC6/GATA4/HtrA1 axis as a critical driver of cellular senescence in the inner ear. GATA4 nuclear translocation, facilitated by HDAC6 downregulation, transcriptionally activates HtrA1, promoting hair cell senescence, SASP, and audio‐vestibular dysfunction in models of Ménière's disease and age‐related audio‐vestibular ...
Na Zhang, Na Li, Yan Wang, Jing Zhang, Jiahui Liu, Lei Chen, Yongdong Song, Yurong Mu, Yuechen Han, Yafeng Lyu, Xiaofei Li, Hanyue Wang, Jing Wang, Yao Lu, Zhaomin Fan, Daogong Zhang, Haibo Wang   +16 more
wiley   +1 more source

Dendritic Cell Therapy in Immuno-Oncology: A Potentially Key Component of Anti-Cancer Immunotherapies. [PDF]

Cancers (Basel)
Marchelek EM, Nemeth A, Mohak S, Varga K, Lukacsi S, Fabian Z.   +5 more
europepmc   +1 more source

Fibrates Inhibit PLTP‐induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs

Advanced Science, EarlyView.
Phospholipid transfer protein(PLTP) plays a critical role in forming a complex with kinase A (AURKA) and P65. This interaction facilitates phosphorylation of P65 at Ser536, leading to the activation of the NF‐κB signaling pathway. Ultimately, this leads to the upregulation of downstream cytokines, including IL‐6, IL‐8, and CSF‐1, which promotes M2 ...
Xinyue Liang, Yaning Li, Jianxun Cai, Lisi Luo, Pengfei Yang, Yutong Chen, Jiancong Zhou, Yan Zeng, Jiaping Yu, Weiyu Zhang, Wenzheng Pang, Yufang Li, Chunhua Wen, Jian Li, Linjuan Zeng   +14 more
wiley   +1 more source

Engineering antibody-armed oncolytic viruses: design strategies, synergistic mechanisms, and clinical translation. [PDF]

Front Immunol
Kang X, Yang X, Wu H, Tong X, Wang S.
europepmc   +1 more source

[Malignant urologic neoplasms and HLA antigen (1)].

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1983
I, Kondo, H, Fujii, K, Suzuki, A, Kohdaira, K, Saito   +4 more
openaire   +1 more source

TRMT6‐Mediated m1A Modification of CDK9 mRNA Is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma

Advanced Science, EarlyView.
TRMT6‐mediated m1A modification in CDK9 mRNA enhances its mRNA stability and translation efficiency, thereby increasing the protein levels of CDK9. Upregulated CDK9 promotes the progression of HCC by elevating the levels of oncogenic factors including p‐STAT3, MCL1, and BCL‐2. On the other hand, CDK9 phosphorylates TARDBP at Ser254 to activate HBV core
Rui Zhang, Dandan Zong, Rui Liu, Yubo Wang, Qingqing Gu, Yao Yao, Wenfang Zheng, Mengmeng Yuan, Simeng Wang, Rongrong Cui, Daxu Li, Siwen Dang, Peng Hou   +12 more
wiley   +1 more source

Therapeutic cancer vaccines in pancreatic cancer. [PDF]

Front Immunol
Wang Y, Huang P, Li C, Tu S, Yang H.
europepmc   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, EarlyView.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source